Nyakatura Elisabeth K, Frei Julia C, Lai Jonathan R
Department of Biochemistry, Albert Einstein College of Medicine , 1300 Morris Park Avenue, Bronx, New York 10461, United States.
ACS Infect Dis. 2015 Jan 9;1(1):42-52. doi: 10.1021/id500025n. Epub 2014 Dec 18.
The Ebolaviruses are members of the family Filoviridae ("filoviruses") and cause severe hemhorragic fever with human case fatality rates as high as 90%. Infection requires attachment of the viral particle to cells and triggering of membrane fusion between the host and viral membranes, a process that occurs in the host endosome and is facilitated by the envelope glycoprotein (GP). One potential strategy for therapeutic intervention is the development of agents (antibodies, peptides, and small molecules) that can interfere with viral entry aspects such as attachment, uptake, priming, or membrane fusion. This paper highlights recent developments in the discovery and evaluation of therapeutic entry inhibitors and identifies opportunities moving forward.
埃博拉病毒是丝状病毒科(“丝状病毒”)的成员,可导致严重出血热,人类病死率高达90%。感染需要病毒颗粒附着于细胞,并引发宿主细胞膜与病毒膜之间的膜融合,这一过程发生在宿主内体中,并由包膜糖蛋白(GP)促进。治疗干预的一种潜在策略是开发能够干扰病毒进入过程中诸如附着、摄取、启动或膜融合等方面的药物(抗体、肽和小分子)。本文重点介绍了治疗性进入抑制剂发现与评估方面的最新进展,并确定了未来的机会。